Currently trading significantly below fair value of $1 based on the current $28m run rate and valuation of peer companies often well above 10x sales during the high growth stages. Less then 2x revenue is simply grossly undervalued for a stock of this quality. The hard numbers (the facts) speak for themselves:
(I try to follow and copy our "friend" with a one liner, but I can't bring myself to make such a mindless and useless post based on nothing but my thoughts - don't know how he does it)
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-376
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.010(4.76%) |
Mkt cap ! $50.39M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.5¢ | 21.0¢ | $84.60K | 389.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100224 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 23847 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |